Bioconjugates & Beyond

A Compass for Your ADC Development Journey
ADCs are a growing and complex class of therapeutics that present unique challenges but offer incredible patient benefits. Bioconjugation is a critical element in developing ADCs and other targeting and delivery agents.
Early assessment of bioconjugation technology options, as well as de-risking the payload, linker, and biologics targeting molecule, is crucial to optimizing the path to first-in-human studies.
If you are working on an ADC, monoclonal antibody, bispecific, or small molecule (especially in the oncology field), this talk will highlight how Lonza can partner with you from molecule design all the way through de-risking and development to clinical manufacture.
Lonza’s integrated approach and depth of expertise offer you unique advantages and real timeline optimization.
Three Takeaways
- Discover early phase drug development strategies
- Connect in person with industry leaders
- Learn from real-world examples
Speakers
- Raymond Donninger, MB ChB, Senior Director Commercial Development, Early Development Services
- Raphael Frey, PhD , Director Commercial Development Bioconjugates
- Mamiko Ninomiya, PhD, Project Leader, Preclinical Development Bioconjugates
About Lonza Biologics
Lonza Biologics is a fully integrated CDMO that offers innovative development and manufacturing services and technologies from late-phase drug discovery to market supply, from drug substance to drug product across a variety of molecule types.
Information
- When: to
- Where: Bistro Merge, The Spark building, Medicon Village, Scheeletorget 1, Lund
- Organizer: Medicon Village in collaboration with Lonza Biologics
- Language: English
Registration
Please register no later than Monday 24 February 2025
Category
- Seminarium/utbildning
Contact information
- Lottie Norrsén
- lottie.norrsen@mediconvillage.se